SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE(®) for critically ill pediatric patients with acute kidney injury (AKI)

SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications